(Sharecast News) - AstraZeneca has received the green light for its Fasenra drug in the US, used to treat patients with a rare inflammatory disease.
Fasenra, otherwise known as benralizumab, is used to treat adult patients with eosinophilic granulomatosis with polyangiitis or EGPA - an immune-mediated vasculitis (inflammation of small to...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE